Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Clinical trial NCT03012620 · COMPLETED

Trial details

NCT number: NCT03012620
Sponsor: UNICANCER
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Sarcoma Ovarian Neoplasm Central Nervous System Neoplasm Thyroid Neoplasm Carcinoma, Neuroendocrine Neoplasms, Germ Cell and Embryonal NK/T-cell Lymphoma

Start date: 2017-07-05
Primary completion: 2022-12-26
Enrollment: 334

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.